REVIEW



The relationship between muscle mass changes and protein or energy intake in critically ill children: A systematic review and meta-analysis

Lewis J. Stacey¹ \square | Frederic V. Valla MD, PhD² \square | Chao Huang PhD³ \square | Paul Comfort BSc, PhD⁴ \square | Corinne Jotterand Chaparro RD, PhD⁵ \square | Lynne Latten RD, BSc⁶ \square | Lyvonne N. Tume RN, PhD^{1,7} \square

¹Edge Hill University, Ormskirk, UK

²Pediatric Intensive Care, Hospices Civils de Lyon, Lyon, France

³Institute for Clinical and Applied Health Research and Hull York Medical School, University of Hull, Hull, UK

⁴Directorate of Psychology and Sport, University of Salford, Salford, Greater Manchester, UK

⁵Department of Nutrition and Dietetics, Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland

⁶Paediatric Critical Care Dietician, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

⁷Pediatric Intensive Care Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

Correspondence

Lyvonne N. Tume, RN, PhD, Pediatric Intensive Care Unit, Alder Hey Children's NHS Foundation Trust, East Prescott Rd, Liverpool L12 2AP, UK. Email: Lyvonne.tume@edgehill.ac.uk

Linali. Lyvonne.tume@eugenil.ac.

Funding information

This work was funded by the National Institute of Health Research (NIHR) New Medical Schools Intercalation and Internship Programme (NMSIDI-2023-007) Integrated Academic Training. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health & Social Care.

Abstract

Survivorship after pediatric critical illness is high in developed countries, but many suffer physical morbidities afterwards. The increasing focus on follow-up after critical illness has led to more pediatric studies reporting muscle mass changes (using ultrasound), albeit with different results. A systematic literature review was undertaken examining muscle mass changes, assessed by ultrasound of the quadriceps femoris muscle in children who are critically ill. Secondary objectives were to determine if muscle mass was associated with protein intake and/or energy. Databases were searched in July 2024. Eligible experimental or observational studies, published from January 2010 to July 2024 and including children who are critically ill that were aged between ≥37 weeks' gestational age and 18 years who were admitted to the pediatric critical care unit were included. The Joanna Briggs Institute for observational studies critical appraisal instrument was used to assess studies for methodological quality. One hundred and thirty-five studies were screened, and eight prospective cohort studies were included, involving 411 children. Overall, muscle mass changes reported in seven out of eight of the papers showed a pooled mean muscle mass loss of 8.9% (95% confidence interval [CI] 6.6-11.4) from baseline to days 5-7. Five of the eight publications defined muscular atrophy as a decrease in muscle mass of >10%. Using this cutoff, 92 (49.2%) children developed muscular atrophy during their PICU admission. Overall, muscle mass decreased by nearly 10% during a child's first week in PICU, with almost half of children developing muscular atrophy during their admission.

KEYWORDS

child, intensive care, muscle, pediatric, sarcopenia

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2024} The Author(s). Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition.

INTRODUCTION

Mortality in pediatric intensive care (PICU) is very low in developed countries.¹ Most children now survive critical illness but often suffer from ongoing physical, cognitive, and psychosocial morbidities, now known as PICS-p,² which can afflict up to 50% of children.³ After discharge from PICU, studies have reported that children have difficulties in their physical function ranging from mild to severe disabilities.^{4,5}

Point of care ultrasound (POCUS) is a tool increasingly used in critical care for a variety of applications, including assessing soft tissue.⁶ Valla et al validated a technique of guadriceps ultrasound measurement to assess muscle mass in children, showing POCUS could reliably detect the extent of muscle mass loss in children.⁷ It is important to identify children at risk of muscle mass loss to be able to intervene earlier, with the aim of minimizing the long-term consequences. Minimizing muscle atrophy is important as muscle wasting (using POCUS) has been increasingly reported in this population,⁷⁻¹⁴ albeit with differing results. Therefore, we aimed to systematically review literature examining muscle mass changes, assessed by ultrasound of the quadriceps femoris muscle, in critically ill children. Our secondary objectives were to determine if muscle mass is associated with protein intake and/or energy intake, or other factors such as severity of illness, length of hospital stay, length of mechanical ventilation, and use of medications (including steroids and neuromuscular blockade).

MATERIALS AND METHODS

Protocol and registration

We undertook a systematic review following the Joanna Briggs Institute framework.¹⁵ The review protocol was registered in Open Science Framework¹⁶ and reported according to PRISMA 28 and PRISMA S29 reporting guidelines.^{17,18}

Definitions

For this study we defined muscular atrophy as a >10% decrease in muscle mass measurement during the child's PICU stay.

Outcomes and eligibility criteria

The primary outcome was muscle mass changes in the quadriceps femoris muscle in children who are critically ill. The secondary outcomes were protein intake, energy intake, and other risk factors, such as severity of illness, length of hospital stay, length of mechanical ventilation, and use of medications (such as steroids and neuromuscular blockade).

Search strategy

A comprehensive search strategy was designed (in conjunction with an information specialist) and adapted to answer the question: what are the muscle mass changes in the quadriceps femoris muscle in children who are critically ill?

A secondary question was: what is the association of this muscle mass loss with protein and/or energy intake, or other risk factors, such as severity of illness, length of hospital stay, length of mechanical ventilation, and use of medications (such as steroids and neuromuscular blockade).

The following databases: MEDLINE, CINAHL Complete, Embase, Cochrane Library Central Register of Controlled Trials and trial registers, such as Clinicaltrials.gov and the World Health Organization's International Clinical Trials Registry. The full search strategy is shown in Table S1. The search included information sources/databases published from January 1, 2010, to July 31, 2024. This date range was chosen as the first international guidelines for POCUS in critical care were published in December 2020,¹⁹ so we selected a decade before this date and could find no papers published before this time.

Study selection

This review included experimental or observational studies that included term neonates (born at \geq 37 weeks' gestation) up to 18 years old who were admitted to PICU for a minimum of 48 h and had quadriceps muscle mass assessed by ultrasound. Any studies involving preterm neonates and/or adults were excluded.

All identified citations were collated and uploaded onto Rayyan software TM (Qatar Computing Research Institute) for screening, and any duplicated sources were removed. The titles and abstracts were initially screened by two independent reviewers (L. S., L. T.) for assessment against the inclusion criteria. Any potentially relevant studies were retrieved in full text for checking. Full-text papers were then assessed against the inclusion criteria by two independent reviewers (L. S, L. T.), and any disagreements at any stage were resolved by a third reviewer (F. V.).

Data extraction

Data was extracted into a modified version of the Joanna Briggs Institute (JBI) tool. When key data was missing, authors were contacted. Included studies were critically appraised using the JBI critical appraisal tool for analytical studies.²⁰ Each study was evaluated across eight domains to assess the risk of bias. A figure illustrating the reviewers' judgments was generated using the robvis tool.²¹

Data analysis

The characteristics of the included studies were summarized in a summary table. The data was extracted into a Microsoft Excel file for a meta-analysis. We utilized the metafor package in R language (version 4.2) to assess the percent loss in muscle mass during days 5–7 from baseline.²² This analysis was conducted by random effect model, with the level of study heterogeneity represented by l^2 . Because the correlation coefficient between baseline and days 5–7 was not reported, we assumed it was zero. One study reported the study outcomes for two subgroups, which were aggregated for meta-analysis. Three studies reported median and interquartile range (IQR) of the study outcome, we transferred them to a mean and SD, following Cochrane guidance.²³

For outcomes where a meta-analysis was not possible, studies were presented narratively. The data were presented by calculating an overall median muscle mass change for all the studies and presented in relation to protein intake and/or energy intake and other risk factors, such as length of stay, use of medication (such as steroids and neuromuscular blockers), and severity of illness scores. Muscular atrophy, defined as a decrease in muscle mass percentage >10%, was also summarized and presented.

RESULTS

Study selection

One hundred and thirty-five publications were identified; 61 of these were duplicates and removed. Finally, eight studies were included in this review⁷⁻¹⁴ (Table 1), as illustrated in the PRISMA diagram (Figure 1). Included studies were published between 2017 and 2024, and all were prospective observational cohort studies.

Study characteristics

Overall, there were 411 children included in these studies, 164 (39.9%) female and 247 (60.1%) male. The median age was reported in seven of the eight studies and was 37.2 months (range, 6–110.4 months), and median weight, reported in six studies was 14.8 kg (range, 4.42–21.4 kg). Studies took place in the following countries: United Kingdom (2), United States (2), Brazil (1), Singapore (1), India (1), and Spain (1).

Pooled analyses

Primary outcome

As shown in Table 1, the median percentage changes in muscle mass from baseline to PICU days 5–7 was measured in four of the eight studies. When we calculated the median percentage change of muscle mass for these studies, it was –9.8% (range, 3%–13%).^{7,8,13} In addition, the percentage change was measured in seven of the eight studies (using mean or median).^{7,8,10–14} When we pooled the results, the meta-analysis showed a mean muscle mass loss of 8.9% (95% confidence interval [CI]: 6.4–11.4%). This was also reported as a forest plot (Figure 2). The l^2 for

this random effect model was 72.3%, confirming the high level of heterogeneity. Excluding the three studies that reported median and IQR, the pooled results show a 9.1% (95% Cl, 6.1–12%) muscle loss and 74.5% heterogeneity. Figure 3 reports the forest plot.^{10–12.14} Five studies reported muscular atrophy, consistently defined as a decrease in muscle mass >10% of baseline. Using this definition, around half of children (*n* = 92; 49.2%) developed muscular atrophy during their PICU stay.

Secondary outcomes

Impact of protein intake

As shown in Table S2, four studies provided protein intake from days 1-7 of PICU stay.^{7,8,11,13} All studies showed lower protein intakes compared with the minimum recommended intake of 1.5 g/kg/day for this population²⁴ and a decrease in muscle mass between baseline and days 5-7 after PICU admission. However, all studies provided different variables around protein intake, which complicates the comparison. Two studies provided a percentage intake of 1.5 g/kg/day.^{8,11} In the first study,⁸ the median protein intake reached 55% (IQR, 20.2-68.2%) and had a muscle mass loss of 3% (95% Cl, -18.7%) on day 7. In the second study,¹¹ the mean protein intake reached 72% (95% CI, 67-83%), and the mean muscle mass loss was $-13.33\% \pm 13.56\%$. In the study of Valla et al,⁷ the median percentage cumulative protein intake deficit at day 5 was -58.9% (IQR, -74.4 to -28.0%), and the median muscle mass change was -9.8% (IQR, -13 to -3%). The last study¹³ provided the cumulative protein intake deficit at day 5 in g/kg/day, at day 7, the authors found a mean deficit of -0.34 g/kg/day (95% CI, -1 to 0 g/kg/day) and a median change in muscle mass of -13% (IQR, -24 to -0.5%).¹³

Impact of energy intake

Similarly, there was no consistency among studies in the definition of energy intake. Only three studies reported energy intake from days 1 to 7 of PICU admission ^{7,8,11} at baseline, and at days 5–7 after PICU admission, as shown in Table S3. One study defined energy intake as the percentage deficit compared with the Schofield equation, finding a median deficit of -55.3% (IQR, -64 to -16.5%) and a median change in muscle mass of -9.8% (IQR, -13.7 to -0.5%) by day 5.⁷ Tume et al.⁸ defined energy intake as a percentage of goal intake based on the Schofield equation, in this study they found a median energy intake of 49% (IQR, 23.3%–65.7%) and had a median change in muscle mass of -3% (95% CI, -18.7) by day 7. Finally, a third study defined energy intake as the percentage intake of 73% (95% CI, 62%–84%) and a mean muscle mass loss of -13.33 \pm 13.56%.¹¹

Risk factors for worse muscle mass loss

The main risk factors that were identified in the studies were: length of PICU stay, length of mechanical ventilation, length of hospital stay,

| Study reference | Study aesign | Country and study duration (months) | Total number of participants recruited and number followed up, if different (%) | Study demographics: Age; sex distribution; weight; illness mortality score; adjusted z score(s) | Outcomes measured | Ultrasound method used | Data collection time frame | Muscle value results: QF thickness, QF CSA, muscle atrophy, and muscle(s) echogenicity |
|--------------------------------|---|--|--|---|---|---|---|---|
| Valla et al ⁷ | Prospective cohort study; Single center | UK; Duration: November 2015 to April months) months | 17 | Age, median (IQR): 47 (5-126) months; Sex, number (%): 2 (11.8%) women, 15 (88.2%) men; Weight: 20 (7.8-29.5) kg; BMI z score: 0 (-0.75 to 0.7) | QF thickness, muscle atrophy, age, weight, length of PICU stay, BMI z score, use of sedative drugs, use of neuroblocking agents, MV duration, energy intake, protein intake | US Method: Performed with the ultrasound in B-mode and perpendicular to the skin. The patient was placed supine and only one leg was measured, which was fully extended and positioned in neutral position. To calculate QF thickness the anterior heads of RF and VI muscles thickness were measured. Measurements were either cooperative or sedated. Four measurements were gathered, two transverse measurements, and two longitudinal and averages of the two measurements were obtained; Location: Used measuring tape to identify the widest portion of the thigh, then measured the distance of the patella and recorded this value. This area was marked with an indelible marker pen, and this was the site of all measurements; US Device: Vivid S6 or SonoSite EDGE with transducer frequencies of 9-13 MHz; Operator(s): seven operator's Reliability: Intraoperator rand interoperator repeatability and reproducibility studies were conducted with seven operators to develop the technique. | Within 24 h of admission, day 5, Final measurement | Change in QF thickness from admission, %, median (IQR); day 5: -9.8 (-13.7 to 0.5); Last measurement: -13.3 ; (-25.4 to -8.7); (-8.7); (-7.7); dat frickness, cm, median (IQR); admission: 2.25 ($1.72-2.79$); dat $5.2.11$ ($1.36-2.43$); last measurement: 1.75 ($1.36-2.33$); muscle atrophy (participants > 10% decrease in QF thickness); No (%): day 5: 7 (41%); last measurement: 10 (59%) |
| Johnson et al ¹⁰ | Prospective cohort study; Single center (PICU) | United States; Duration: June 2015 to | 34 | Age, mean (95% Cl): 5.42 (3.44–7.40) years; | QF thickness, EIM-derived fat changes, Length of PICU stay, | US method: Measured muscle thickness with a bedside ultrasound and electrical impedance using an EIM device. Measurements were | Timings: Enrolment then every 5–8 days | Change in quadriceps thickness, %, mean (95% Cl): Day 5/6 8.62; (-15.7 to -1.54) <i>P</i> = 0.0187; |

TABLE 1 Summary of evidence table.

| Muscle value results: QF thickness, QF CSA, muscle atrophy, and muscle(s) echogenicity | Muscle atrophy (participants ≥ 10% decrease in QF thickness), No (%): 16 (53%) | Change in quadriceps thickness, %, mean \pm SD; Day 7 Subgroup 1: -12.83 \pm 14.07, P < 0.001; Day 7 Subgroup 2: -13.81 \pm 13.05, P < 0.001; Day 14 Subgroup 2: -16.35 \pm 13.04, P < 0.001; QF thickness, cm, mean \pm SD; Baseline Subgroup 1: 0.65 \pm 0.23; Baseline Subgroup 1: 0.65 \pm 0.22; Day 7 Subgroup 1: 0.65 \pm 0.17; Day 7 Subgroup 2: 0.53 \pm 0.17; Day 7 Subgroup 2: 0.53 \pm 0.17; Day 14 Subgroup 2: 0.52 \pm 0.17; Day 14 Subgroup 2: 0.52 \pm 0.17; Muscle atrophy Muscle atrophy from baseline to day 7 | RF CSA, % change from baseline, mean (95% Cl); Day 3: -8.4 (-20.2 to 3.5) <i>P</i> = 0.147; (Continues) |
|--|--|--|---|
| Data collection time frame | until PICU discharge | Timings: Baseline, day 7, day 14 | Timings: Within 48 h of PICU admission, then days 3, 7, and |
| Ultrasound method used | taken three times, and an average gathered; Location: Temporarily marked and regularly reinforced a position ½ distance from ASIS to patella's superior edge; US Device: Sonosite Edge II (FUJIFILM Sonosite Inc) using a 13–6 MHz 6 cm linear probe (L25); Operator(s); Reliability: Performed interrater to ensure results were reliable | US Method: Used in B-mode, with the transducer placed perpendicular to the skin. Participants' muscles were relaxed and placed in a supine position with the knee in passive extension and neutral rotation. Maximum compression was applied in the transverse section; Location: Right leg along the long axis of the anterior thigh, two-thirds distance from the ASIS to superior patella border; US Device: Vivid Q (GE Healthcare) equipped with a linear probe 5-13 MHz; Operator(s): Single operator by a qualified pediatric ultrasound instructor; Reliability: Performed intrarater variability analysis. | US Method: Measurements were taken with the child in a supine position with legs extended and neutral. Transverse B-mode was |
| Outcomes measured | Length of hospital stay, MV-free days, Glucocorticoids use, Neuromuscular blockade use | QF thickness, QF % change, Daily intake, MV need, Length of PICU stay, In- hospital mortality | RF CSA, RF echogenicity, Quadriceps fat thickness, |
| Study demographics: Age; sex distribution; weight; illness mortality score; adjusted z score(s) | Sex, number (%): 15 (45.5%) women; 18 (54.5%) men; BMI, mean (95% CI): 17.23 (15.76-18.70) kg/m ² ; PRISM III, mean (95% CI): 14.72 (4.00-30.00) | Age, median (IQR): 12 (4.0–42.5) months; Sex, number (%): 47 (39.5%) women; 72 (60.5%) men; WAZ Score, median (IQR); -1.29 (-2.85 to 0.04), measured in <10 years (<i>n</i> = 108); BMI Z-score, median (IQR); -0.62 (-2.17 to 0.24), measured in all ages; PIM2, median (IQR); 2.6 (1.3–5.6) | Age, median (IQR): 3.1 (0.8 <i>-9</i> .2) years; |
| Total number of participants recruited and number followed up, if different (%) | | 119; Subgroup 1: 55 (values measured baseline and day 7); Subgroup 2: 32 (values measured baseline, day 7 day 14) | 73; Follow-up: 44/ 73 (60.2%) |
| Country and study duration (months) | May 2016 (11 months) | Brazil; Duration: July 2017 to April 2018 (9 months) | Singapore; Duration: January 2015 to October |
| Study aesign | | Prospective cohort study; Single center (PICU) | Prospective cohort study; Single center (PICU) |
| Study reference | | de Figueiredo et al ¹¹ | Ong et al (2023) |

TABLE 1 (Continued)

| e | Study aesign | Country and study duration (months) | Total number of participants recruited and number followed up, if different (%) | Study demographics: Age; sex distribution; weight; illness mortality score; adjusted z score(s) | Outcomes measured | Ultrasound method used | Data collection time frame | Muscle value results: QF thickness, QF CSA, muscle atrophy, and muscle(s) echogenicity |
|---|--|---|--|--|---|--|--|--|
| | | 2018 (45 months) | | Sex, number (%): 34 (46.6%) women; 39 (53.4%) wonen; 39 Weight, median (IQR): 14.6 (7,5-30.3) kg; BMI Z-score, median (IQR); -0.73 (-1.79 to 0.42); PIM3, median (IQR): 0.80 (0.40-2.20) | Protein intake, Energy intake, Length of MV | conducted on the right leg. Images were obtained in triplicate and average values were used; Location: Halfdistance from the ASIS to the superior border of the patella, in children ≥6 years, a distance of two-thirds from ASIS was used; US Device: LOGIQe, GE Healthcare, US Device: LOGIQe, GE Healthcare, Chicago, IL, USA with a 5–13 MHz linear array transducer; Operator(s): Single operator; Reliability: Interrater correlation was calculated. | 10, PICU discharge and hospital discharge; Follow-up: At 6-12 months after hospital discharge, median (IQR): 6.7 months (6.0-7.7) | Day 7: -6.2 (-21.8 to 9.4) P = 0.400; Day 10: -2.2 (-21.9 to 17.7) P = 0.812; R echogenicity, % change from baseline, mean (95% CI); PICU discharge: -3.0 (-11.8 to 5.8) $P = 0.497;$ Hospital discharge: -1.0 (-0.61 to 7.60) $P = 0.346;$ Follow-up: 14.7 (-0.8 to 30.2) P = 0.063; Muscle atrophy (participants > 10% decrease in QF thickness), No (%); 41 (56.2%) |
| | Prospective cohort study; Single tertiary care children's hospital | United States; Duration: December 2017 to 2019 (23 months) | 98 | Age, median (IQR): 9.2 (2.2-16.5) years; Sex, number (%): 11 (31%) women 25 (69%) men; Weight, median (IQR): 21.4 (11.8-41.3) kg | QF thickness, Protein intake, Energy intake, Fluid output, Length of hospital stay, Use of paralytic agents, Length of MV | US Method: Measured the combined thickness of RF and VI. Ultrasound images were gathered in B-mode with copious gel, and the patient was placed in the supine position their leg was extended and the transducer was placed and the transducer was placed and such the transducer was placed to the skin. This was repeated for both short axis and long axis to obtain two of each image (4 in total), which was repeated every 3 days until discharge or study day 15; Location: Two of five of the distance from the ASIS to the superior patella border, a surgical pen marked the site; US Device: General Electric Logiq S8 with 9L-D 3.1-10 MHz linear probe or General Electric Nextgen Logiq e with L4-12t-RS 4.2-13 MHz linear probe or General Electric Nextgen Logid e with L4-12t-RS 4.2-13 MHz linear probe or General Electric Nextgen Logid e with L4-12t-RS 4.2-13 MHz linear probe | Timings: Within 72 h of ICU admission, then repeat every 72 h | Change in quadriceps thickness, %, mean ± SD; Day 3: −4.5 ± 6.6; Day 6: −8.2 ± 8.0 |

| | | day); 2(3); 2(3); | ess, () (RR); nues) |
|---|--|--|---|
| s: QF muscle :(s) | | ess from 0.46) to 0.4); 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46) 0.46] 0.46) 0.46]0 | s thickn to -0.5' -0.5) -0.5) (0.5); 55); .71); (Cont |
| e results PF CSA, d muscle | | F thickn (IQR) (-0.1 to (-0.1 to (-0.3 2 5; (1.42-2.1 (1.43-2, (1. | uadricep QR); 7 (-13.4 (-24 to s, cm, m s, cm, m (1.38-2 (1.3-1.5 (1.13-1) |
| scle valu kness, C phy, and | | nge in C 3 0.09 7 -0.03 7 -0.03 7 -0.03 7 -0.03 1 1.58 3 1.82 7 1.66 7 1.66 7 1.056 1 3 3.5.2 3 3.6.27 7 40.92 7 40.92 7 20.48 7 20.48 7 20.48 7 20.48 7 20.04 7 20.05 7 20.04 7 20.05 7 20.04 7 20.05 7 20.05 | nge in q nedian (1 3: -4.6 7: -13 7: -13 7: 1.56 3: 1.45 7: 1.37 7: 1.37 |
| Mus thic atro echo | | 1, Characteristic Construction D_{a} (Characteristic Construction) | C C C C C C C C C C C C C C |
| collection rame | | s: Days 7 of .ay | ss: Withi fter g MV, ted at 1 week veekly veekly sxtubatec |
| Data c time f | | Timing 3, and ICU st ICU st | Timing 24 h a startin Repea Repea then v then v until e |
| | (two ediatric one lass o | nents leg nd the endicular and and bint le pen; co, using Hz tor, tor, udy in 20 | alla et al hbined patient and their heiral ode with three three superior was |
| used | berators ts, two p ngs, and ed intrac howed n e. | neasuren pine witt Irotation mode ar ced perpu- ch at a p ch at a p ch at a p n indelib n indelib n indelib (3-12 M (3-12 M corer stu erver stu | ed the V the con osition i the and i the B-mu taken; that a p SIS and a, which |
| method | : Five of Idiologist e attendi ssident); Perform which s which s | I: Took n atient su using B- using B- using B- using B- tween th tween th tween th tween th and th a with al cX-50, nsducer : Single interobs | 1: Follow fr RF anc fr RF anc supine p sextence erformec erts was cight thig tween A the patel he patel |
| trasounc | berator(s) diatric ra tical care diatric re diatric re diatric re rrelation atistical o | s methoo th the pi rended i rformed insducer the skin cation: F dway be dway be dway be perior bc s Device. S Device | 5 Methou to the to ckness c ckness c in the manual of pious ge pious ge easureme dway be ruder of f |
| 5 | Or Cripe Strocker Str | pape 0 france v v v v v v v v v v v v v v v v v v v | b ai c po para c t tai a C b ai c po para c t tai a C |
| comes | | thickness ogenicity ogenicity rie intak rie intak AV | thickness ein intak gth of Pl gth of Pl ital stay of of roblockir ths, Use emic |
| e: Dut mea | | QF echi echi echi echi echi of h | QF Prot Leng stay Use 3): neu ager syst |
| ohics: Ag weight; score; (s) | | R): 72 s; 36 36 (IQR): 1 (IQR): 1 11); an (SD): an (SD): | R): 6 : 22 19 (IQR): 5 dian (IQR): 2.16); an (IQR): |
| emograf ribution nortality d z score | | edian (IQ b) montf mber (%) women; men; median kg; kg; kg; (18.66) (18.66) (18.66) | edian (IQ months; mber (%) women, men; median (§; ts: -4:13 to -4:13 to 111, medial 112) |
| Study d sex dist illness r adjustee | | Age, me Sex, nuio Sex, nuio (6.2.1%) (6.2.1%) (10-23) | Age, me (0-22) r Sex, nul (53.7%) (46.3%) Weight, (4-12) f (4-12) f BMI z s -0.92 (- PRISM PRISM |
| hber of its and up, if (%) | | | |
| otal nun articipar ecruited umber ollowed ifferent | | m | Ţ |
| ⊢ d z u z p | | 22018 2019 (hs) | : 2020 (hs) |
| Country Ludy luration months) | | ndia; anuration o June 2 17 mont 17 mont | ipain; Juration o June 2 17 mont 17 mont |
| ign c | | udy; 1 udy; 1 a a t are (| ve udy; I L L L L L L L L L L L L L L L L L L L |
| tudy aes | | rospect single ce PICU) of ertiary c nospital nospital | Prospect cohort st ingle center (P |
| S Ce | | | 9 C |
| Study referen | | Jain et | Valver Monto et al ¹³ |

TABLE 1 (Continued)

7

| Muscle value results: QF thickness, QF CSA, muscle atrophy, and muscle(s) echogenicity | Muscle atrophy (participants > 10% decrease in QF thickness), No (%): 23 (56%) | QF thickness, %, mean (95% Cl); Day 1 1.86 (0.93–2.78); Day 3 2.03 (1.16–2.91); Day 5 2 (1.06–2.93); Day 7 1.84 (1.05–2.63); PloU discharge 1.91 (0.98–2.84); Follow-up 2.22 (1.35–3.09); QF CSA, mean (95% Cl) %; Day 1 2.04 (-0.37 to 4.44); Day 3 2.46 (-0.09 to 5.02); Day 5 2.44 (-0.4 to 5.28); Day 7 1.76 (-0.19 to 3.72); PICU discharge 1.62 (-0.17 to 3.41); FICU discharge 1.62 (-0.17 to 3.41); FICU discharge 2.4 (-0.01 to 4.8); To 3.41); FICU discharge 2.4 (-0.01 to 4.8); FICU discharge 2.4 (-0.01 to 4.8); FICU discharge 2.4 (-0.01 to 4.8); Follow-up 3.02 (0.08–5.95); Muscle atrophy (participants > 10% decrease in QF thickness), No (%); 15 (44%) |
|--|---|---|
| Data collection time frame | | Timings: Day 1, 3, 5, 7, and 10 of PICU stay (day 10 was excluded because of limited sample size), PICU discharge, Hospital discharge, Follow-up; At 3 months |
| Ultrasound method used | marked with an indelible marker pen; US Device: SonoSite M-turbo portable ultrasound with a 12 MHz linear transducer; Operator(s): Two operators who are specialists in pediatric critical care; Reliability: Both intraoperator and interoperator studies were conducted. | US method: Used Valla et al method; Location: Quadriceps; US Device: Sonosite (Fujifilm); Operator(s): 99% of measurements were taken by one trained operator; Repeatability: Mean of four measurements (in two different incidences) |
| Outcomes measured | corticosteroids, Length of MV | QF thickness, QF CSA, Protein intake, Energy intake, Exposure to steroids, Exposure to neuromuscular blockade, inflammatory markers (CRP), Length of PICU stay, Length of hospital stay, Duration of MV, Mortality |
| Study demographics: Age; sex distribution; weight; illness mortality score; adjusted z score(s) | | Age, median (IQR): 6.65 ($0.47-57.5$) months; Sex, Number (%): 11 (32.4%) women; 23 ($6.7.6\%$) men; Welf, median (IQR): WAZ score, mean \pm SD and median (IQR): -0.92 (0.0335) and -0.74 (-1.59 to 0.087); PIM3 Score, median (IQR): 0.010 ($0.005-0.038$) |
| Total number of participants recruited and number followed up, if different (%) | | 34; Follow-up: 11/ 34 (36%) |
| Country and study duration (months) | | UK; Duration: September 2021 to December 2022 (15 months) |
| Study aesign | | Prospective cohort study; Single center (PICU) |
| Study reference | | Tume et al ⁸ |

range; MV, mechanical ventilation; PICU, pediatric intensive care unit; PIM2, Pediatric Index of Mortality 3; PRISM, pediatric risk of mortality; QF, quadriceps femoris muscle; RF, rectus femoris muscle; RF, rectus femoris muscle; SD, standard deviation; UK, United Kingdom; US, ultrasound; VI, vastus intermedius muscle; WAZ, weight adjusted z score.

TABLE 1 (Continued)



FIGURE 1 PRISMA 2020 flow diagram for the search following the search criteria.

corticosteroid use, neuromuscular blockade use, and maximal C-reactive protein (CRP) value. Length of PICU stay was reported in seven out of eight studies,^{7–13} with a median value of 10 days (range, 3.9–14). The study involving patients with the longest PICU stay (median of 14 days [IQR, 11–25]) found a muscle mass change of –13% (IQR, –24 to –0.5%). However, the study with a median stay of 3.9 days (IQR, 2.0–12.3 days) had a mean muscle mass of –6.2% (95% CI, –21.9 to 9.4%).

All studies reported length of mechanical ventilation, with an overall median value of 7.2 days (range, 1.4-12).⁷⁻¹⁴ The study involving children with the longest length of ventilation (median of 12 days IQR, 7-23), had a mean muscle mass loss of $-8.2 \pm 8.0\%$. The study with the

median mechanical ventilation length of 1.4 days (IQR, 0.1–8.0) found a mean muscle decrease of -6.2% (95% CI, -21.8 to 9.8%).

Length of hospital stay was reported in four studies with a median value of 25.6 days (range, 15.7–30).^{8,10,13,14} The muscle mass change in the study that had a median length of 30 days (IQR, 18–50) was a median of –13% (IQR, –24 to –0.5%), whereas the study with a length of stay of 15.7 (IQR, 8.87–25.75) days had a median muscle mass change of –3% (IQR, –18.7%).

Three out of eight studies reported neuromuscular blockade (NMB) use, in which 47 (44.6%) of children received neuromuscular blockade.^{8,10,13} Three studies with 17 + 13 participants who received NMB, reported the mean muscle mass change was -8.62 (95% CI,



FIGURE 2 Forest plot showing the percentage mean muscle mass change for seven studies from baseline to days 5–7 after pediatric intensive care unit (PICU) admission.



FIGURE 3 Forest plot showing the percentage mean muscle mass change for four studies from baseline to days 5–7 after pediatric intensive care unit (PICU) admission.

-15.7 to -1.54%), or a median change of -3 (IQR, -18.7%) to -13% (IQR -24 to -0.5%).^{7,9,12}

Maximal CRP was reported in three studies.^{7,8,13} The overall median value of maximal CRP value was 86 mg/L (range, 41.8–139 mg/L), in three out of eight of the publications.^{8,10,13} The study with the median maximal CRP of 139 mg/L (IQR, 61–203 mg/L) had a median change in muscle mass of –13% (IQR, –24 to –0.5%), whilst the study with the lowest median CRP value of 41.8 mg/L (IQR, 19.5–136.9 mg/L) found a lower median change in muscle mass of –3% (IQR, –18.7%).

Quality assessment

All observational studies were considered to be of low-moderate risk of bias based on the JBI tool.²⁰ The results of the quality assessment are presented in Figure 4.

DISCUSSION

This is the first systematic review to summarize muscle mass changes in children who are critically ill. These results show that the median muscle mass loss from admission to days 5–7 in children who are critically ill was 9.8%. These results also show that almost half (49.2%) of participants developed muscular atrophy (defined as >10%) during their PICU stay. These results are consistent with those in adults who are critically ill, in that they found adults lost on average approximately 2% of skeletal muscle per day during their first week of intensive care stay.²⁵

Nutrition is thought to play a crucial role in maintaining muscle mass²⁶ because of its effect on muscle protein synthesis and muscle protein turnover found in animal studies. A systematic review by Ong et al.²⁶ also found that, once nutrition rehabilitation was commenced, the decreased muscle protein synthesis was reversed. In the current review, all studies that reported protein intake observed lower



FIGURE 4 Risk of bias on individual studies assessed by Joanna Briggs Institute Critical Appraisal Checklist for Analytical cross-sectional studies²⁰: author's judgments for each included study.

intakes in comparison with the recommended 1.5 g/kg/day and a decrease in muscle mass.^{27,28} Similar results were observed for energy intake. These findings highlight the challenge of providing adequate protein and energy intake in this population. Despite existing nutrition guidelines,²⁹ adequate intakes are still difficult to achieve for several reasons, such as enteral intolerance, electrolyte abnormalities, fasting for procedures. Strategies such as the presence of a nutrition team in PICU, education, or the use of nutrition protocol, are necessary.

It should be noted that, although sufficient protein intake is required for the maintenance of muscle mass, in the absence of mechanical stimulation from activity, protein and energy intake alone have not been shown to prevent atrophy in bedrest studies.^{30,31} PICS-p can result in physical changes, including muscular weakness, which can impair children's recovery and rehabilitation.^{2,3} This study has described that muscular mass loss does occur in a large proportion of the pediatric critical care population. This is an issue increasingly being recognized in pediatric critical care, and early mobilization or early rehabilitation interventions are being instituted in many PICUs internationally. A systematic review found that, despite the definition of early mobilization varying, it is safe and feasible in this population.³² A more recent study showed more promising results and suggested starting

mobilization within the first 72 h of PICU admission to have the best outcome. $^{\rm 33}$

All studies in this review used a substitute of either quadriceps femoris muscular thickness or the cross-sectional area of one of these muscles to measure the muscle mass. Valla et al.⁷ validated this measurement technique of quadriceps femoris muscular thickness in children. Only three of these eight studies used this validated technique. Seven out of eight studies measured the quadricep thickness, whereas one study measured the cross-sectional area of the rectus femoris muscle. All studies excluded participants who had neuromuscular disease at admission, improving the consistency of results.

All studies described the exact measurement location; however, this was inconsistent, which could introduce bias and produce different muscle thickness values. However, because the location was consistent within each study, the magnitude of change reported in each study should not be notably affected. Furthermore, on protein intake and energy intake, only four and three of the studies, respectively, reported these values, and each of the studies had a different definition for intake. Thus, there are likely to be other variables that impact muscle mass/change that were not evaluated. Nutrition was evaluated crudely in the studies and not in the context of individual patient intakes compared with

Overall, the review is limited by the quality of the evidence available. All the studies are observational studies, and subjective to confounding and bias. Another limitation of this review was the inability to conduct a meta-analysis on the impact of each risk factor on muscle mass because of the differing definitions used. A core outcome set for PICU studies involving nutrition interventions is urgently required to improve the reporting and consistency in future studies. Finally, only two out of eight studies followed up with patients after PICU discharge. In the two studies that did follow-up, the time varied from 3 to 6 months, and attrition was high, reducing numbers even further.^{8,12} Therefore, the long-term impact of muscle mass in critical care remains unknown. Further studies do need to consistently follow-up children for at least 6 months after critical illness, using age-validated functional assessment scores as well as muscle ultrasound. In summary, the methods of measurement of the quadriceps muscle and the studies' results reporting limited the data we could analyze. Despite these limitations, this is the first systematic review to collate and analyze the published studies, clearly identifying the gaps and limitations in the current research and suggesting what future research needs to address.

CONCLUSIONS

This is the first systematic review to examine muscle mass changes in children who are critically ill and showed around a 10% decrease in muscle mass, with half of children experiencing a decrease in muscle mass loss of >10% during their PICU stay. However, these results are based on cohort studies, which are subject to confounding. Evidence from adults who are critically ill does not suggest a benefit of higher calories and/or protein doses in improving outcomes. More adequately powered randomized studies with longer-term follow-up (using consistent definitions) are required to understand this issue further in children.

AUTHOR CONTRIBUTIONS

Lyvonne N. Tume and Frederic V. Valla conceived the study; Lyvonne N. Tume, Frederic V. Valla, Paul Comfort, Corinne Jotterand Chaparro, and Lynne Latten designed the study; Lewis J. Stacey led the acquisition of data; Lewis J. Stacey undertook data collection; Lewis J. Stacey, Chao Huang, and Lyvonne N. Tume analyzed the data; Lyvonne N. Tume, Frederic V. Valla, Corinne Jotterand Chaparro, Paul Comfort, Chao Huang, and Lynne Latten contributed equally to the interpretation of the data; Lewis J. Stacey drafted the manuscript; and all authors critically revised the manuscript, agree to be fully

accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

ORCID

Lewis J. Stacey b http://orcid.org/0009-0006-7051-560X Frederic V. Valla b http://orcid.org/0000-0001-5285-1104 Chao Huang b http://orcid.org/0000-0002-3627-7218 Paul Comfort b http://orcid.org/0000-0002-1131-8626 Corinne Jotterand Chaparro b http://orcid.org/0000-0002-1538-7127

Lynne Latten D http://orcid.org/0000-0003-1620-0114 Lyvonne N. Tume D http://orcid.org/0000-0002-2547-8209

REFERENCES

- Paediatric Intensive Care Audit Network (PICANet). PICANet State of the Nation Report 2024. Accessed August 13, 2024. https:// picanet.org.uk/annual-reporting-and-publications/
- 2. Tang M, Xu M, Su S, Huang X, Zhang S. Post-intensive care syndrome in children: a concept analysis. *J Pediatr Nurs*. 2021;61:417-423.
- Kosinski S, Mohammad RA, Pitcher M, et al. American Thoracic Society. 2020. Accessed September 21, 2024. https://www.thoracic.org/ patients/patient-resources/resources/post-intensive-care-syndrome.pdf
- Bossen D, De Boer RM, Knoester H, et al. Physical functioning after admission to the PICU: a scoping review. *Crit Care Explor.* 2021;3(6): e0462.
- Sankar J, Moodu S, Kumar K, Sankar MJ, Kabra SK, Lodha R. Functional outcomes at 1 year after PICU discharge in critically ill children with severe sepsis. *Pediatr Crit Care Med*. 2021;22(1):40-49.
- Hashim A, Tahir MJ, Ullah I, Asghar MS, Siddiqi H, Yousaf Z. The utility of point of care ultrasonography (POCUS). Ann Med Surg. 2021;71:102982.
- Valla FV, Young DK, Rabilloud M, et al. Thigh ultrasound monitoring identifies decreases in quadriceps femoris thickness as a frequent observation in critically ill children*. *Pediatr Crit Care Med.* 2017; 18(8):e339-e347.
- 8. Tume LN, Simons C, Latten L, et al. Association between protein intake and muscle wasting in critically ill children: a prospective cohort study. *JPEN J Parenter Enteral Nutr.* 2024;48(5):615-623.
- Jain A, Sankar J, Kabra SK, Jat KR, Jana M, Lodha R. Evaluation of changes in quadriceps femoris muscle in critically iii children using ultrasonography. *Indian J Pediatr*. 2023;90(6):541-547.
- Johnson RW, Ng KWP, Dietz AR, et al. Muscle atrophy in mechanicallyventilated critically ill children. *PLoS ONE*. 2018;13(12):e0207720.
- 11. De Figueiredo RS, Nogueira RJN, Springer AMM, et al. Sarcopenia in critically ill children: a bedside assessment using point-of-care ultrasound and anthropometry. *Clin Nutr.* 2021;40(8):4871-4877.
- Ong C, Lee JH, Wong JJM, Leow MKS, Puthucheary ZA. Skeletal muscle changes, function, and health-related quality of life in survivors of pediatric critical illness. *Crit Care Med.* 2021;49(9):1547-1557.
- Valverde Montoro D, Rosa Camacho V, Artacho González L, Camacho Alonso JM. Thigh ultrasound monitoring identifies muscle atrophy in mechanically ventilated pediatric patients. *Eur J Pediatr.* 2023;182(12):5543-5551.
- Hoffmann RM, Ariagno KA, Pham IV, et al. Ultrasound assessment of quadriceps femoris muscle thickness in critically ill children*. *Pediatr Crit Care Med.* 2021;22(10):889-897.
- 15. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, eds. JBI Manual for Evidence Synthesis. JBI; 2024.

- Tume LN, Valla FV, Comfort P, et al. Muscle mass changes in critically ill children and their relationship with protein or energy intake: a systematic review protocol. JPEN J Parenter Enteral Nutr. 2024;48(5):615-623.
- 17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. *Syst Rev.* 2021;10(1):39.
- 19. Singh Y, Tissot C, Fraga MV, et al. International evidence-based guidelines on Point of Care Ultrasound (POCUS) for critically ill neonates and children issued by the POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care (ESP-NIC). *Crit Care*. 2020;24(1):65.
- Moola S, Munn Z, Tufanaru C, et al. Checklist for analytical cross sectional studies. Accessed July 31, 2024. https://jbi.global/sites/default/ files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_ Sectional_Studies2017_0.pdf
- McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods.* 2021;12(1):55-61.
- 22. Viechtbauer W. Conducting meta-analyses in *r* with the **metafor** package. *J Stat Softw.* 2010;36(3):1-48.
- Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing Effect leasures and Computing Estimates of Effect. Accessed August 20, 2024. https:// training.cochrane.org/handbook/current/chapter-06
- Hauschild DB, Ventura JC, Mehta NM, Moreno YMF. Impact of the structure and dose of protein intake on clinical and metabolic outcomes in critically ill children: a systematic review. *Nutrition*. 2017;41:97-106.
- Fazzini B, Märkl T, Costas C, et al. The rate and assessment of muscle wasting during critical illness: a systematic review and metaanalysis. *Crit Care.* 2023;27(1):2.
- Ong C, Lee JH, Leow MKS, Puthucheary ZA. A narrative review of skeletal muscle atrophy in critically ill children: pathogenesis and chronic sequelae. *Transl Pediatr*. 2021;10(10):2763-2777.
- Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the provision and assessment of nutrition support therapy in the pediatric critically ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017;41(5):706-742.

- Jotterand Chaparro C, Laure Depeyre J, Longchamp D, Perez MH, Taffé P, Cotting J. How much protein and energy are needed to equilibrate nitrogen and energy balances in ventilated critically ill children? *Clin Nutr.* 2016;35(2):460-467.
- 29. Tume LN, Valla FV, Joosten K, et al. Nutritional support for children during critical illness: European Society of Pediatric and Neonatal Intensive Care (ESPNIC) metabolism, endocrine and nutrition section position statement and clinical recommendations. *Intensive Care Med.* 2020;46(3):411-425.
- Trappe TA, Burd NA, Louis ES, Lee GA, Trappe SW. Influence of concurrent exercise or nutrition countermeasures on thigh and calf muscle size and function during 60 days of bed rest in women. *Acta Physiol*. 2007;191(2):147-159.
- Trappe S, Creer A, Minchev K, et al. Human soleus single muscle fiber function with exercise or nutrition countermeasures during 60 days of bed rest. Am J Physiol. 2008;294(3):R939-R947.
- Cuello-Garcia CA, Mai SHC, Simpson R, Al-Harbi S, Choong K. Early mobilization in critically ill children: a systematic review. J Pediatr. 2018;203:25-33.e6.
- Chapple LS, Parry SM, Schaller SJ. Attenuating muscle mass loss in critical illness: the role of nutrition and exercise. *Curr Osteoporos Rep.* 2022;20(5):290-308.
- 34. World Health Organization. Protein and Amino Acid Requirements in Human Nutrition: Report of a Joint FAO/WHO/UNU Expert Consultation. World Health Organization; 2007.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Stacey LJ, Valla FV, Huang C, et al. The relationship between muscle mass changes and protein or energy intake in critically ill children: a systematic review and meta-analysis. *J Parenter Enteral Nutr.* 2024;1-13. doi:10.1002/jpen.2715